US4397854A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
Assignee: Warner Lambert Co LLC
•
Filing: 1981-11-30
•
Granted: 1983-08-09
•
Expires: 2001-11-30
Abstract
Abstract Substituted 6-phenyl-3(2H)-pyridazinone compounds are useful as cardiotonic agents. Said compounds cause a significant increase in myocardial contractility in the anesthetized dog. Said compounds are produced by reacting substituted gamma -oxobenzenebutanoic acids with suitably substituted hydrazines to provide 6-phenyl-4,5-dihydro-3(2H)-pyridazinones which are dehydrogenated to the desired product. The intermediate 6-phenyl-4,5-dihydro-3(2H)-pyridazinones are themselves useful as cardiotonic agents.
Inventors
- 👤 Ila Sircar
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 15:19
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/50
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
153 words
The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form in a pharmaceutically acceptable carrier to such patient an effective amount of a compound having the structural formula ##STR5## wherein represents a double or single bond between two carbon atoms; R is hydrogen, lower alkyl, dialkylaminoalkyl or hydroxyalkyl; R 1 and R 2 are independently hydrogen, lower alkyl or phenylmethyl with the proviso that at least one of them is hydrogen; Y and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, phenoxy, CN or NR 3 R 4 wherein R 3 is hydrogen or lower alkyl and R 4 is hydrogen, lower alkyl or ##STR6## wherein R 5 is hydrogen or alkyl containing one or two carbon atoms; wherein lower alkyl and lower alkoxy contain one to three carbon atoms; and the pharmaceutically acceptable salts thereof.
Claim 2
Independent Claim
153 words
The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form in a pharmaceutically acceptable carrier to such patient an effective amount of a compound having the structural formula ##STR5## wherein represents a double or single bond between two carbon atoms; R is hydrogen, lower alkyl, dialkylaminoalkyl or hydroxyalkyl; R 1 and R 2 are independently hydrogen, lower alkyl or phenylmethyl with the proviso that at least one of them is hydrogen; Y and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, phenoxy, CN or NR 3 R 4 wherein R 3 is hydrogen or lower alkyl and R 4 is hydrogen, lower alkyl or ##STR6## wherein R 5 is hydrogen or alkyl containing one or two carbon atoms; wherein lower alkyl and lower alkoxy contain one to three carbon atoms; and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
43 words
The method according to claim 1 wherein said compound has the structure: ##STR7## wherein R and R 2 are hydrogen or lower alkyl, R 1 is hydrogen and Y and Z are as defined in claim 1 and the pharmaceutically acceptable salts thereof.
Claim 4
Dependent Claim
30 words
The method according to claim 1 wherein said compound has the structure: ##STR8## wherein R, R 1 , R 2 , Y and Z are as defined in claim 2.
Claim 5
Dependent Claim
24 words
The method according to claim 2 wherein said compound is: a. 6-phenyl-4,5-dihydro-3(2H)-pyridazinone b. 6-(3,4-dichlorophenyl)-4,5-dihydro-3(2H)-pyridazinone c. 6-(3,4-dimethoxyphenyl)-4,5-dihydro-3(2H)-pyridazinone d. 6-(3,4-dihydroxyphenyl)-4,5-dihydro-3(2H)-pyridazinone e. 6-(4-acetamidophenyl)-4,5-dihydro-3(2H)-pyridazinone f. 5-methyl-6-(4-acetamidophenyl)-4,5-dihydro-3(2H)-pyridazinone g. 2-methyl-6-phenyl-4,5-dihydro-3(2H)-pyridazinone
Claim 6
Dependent Claim
24 words
The method according to claim 3 wherein said compound is: a. 6-phenyl-3(2H)-pyridazinone b. 6-(3,4-dichlorophenyl)-3(2H)-pyridazinone c. 6-(3,4-dimethoxyphenyl)-3(2H)-pyridazinone d. 6-(3,4-dihydroxyphenyl)-3(2H)-pyridazinone e. 6-(4-acetamidophenyl)-3(2H)-pyridazinone f. 5-methyl-6-(4-acetamidophenyl)-3(2H)-pyridazinone g. 2-methyl-6-phenyl-3(2H)-pyridazinone
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-08-08 | 1987-02-07 | 1987-08-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-08-08 | 1991-02-07 | 1991-08-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-08-08 | 1995-02-07 | 1995-08-09 | $7700.00 | Window Closed / Lapsed |